Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study
- PMID: 20299377
- PMCID: PMC2863974
- DOI: 10.2215/CJN.07171009
Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study
Abstract
Background and objectives: The severity of anemia at which to initiate erythropoiesis-stimulating agent (ESA) treatment in nondialysis chronic kidney disease (CKD) patients is unclear. Risk of mortality, hospitalizations, and blood transfusion were compared among nondialysis CKD patients with "early" versus "delayed" ESA initiation.
Design, setting, participants, & measurements: A retrospective cohort study was conducted on CKD (estimated GFR <60 ml/min/1.73m(2)) outpatients in the national Veterans Administration who were initiated on ESAs. Patients with ESRD, gastrointestinal bleeding, chemotherapy, or hematologic malignancy were excluded. Patients were characterized as having early [hemoglobin (Hb) 10.0 to 11.0 g/dl] or delayed (Hb 8.0 to 9.9 g/dl) ESA initiation. A propensity score comprising demographic, clinical, and laboratory variables was used to select a 1:1 matched cohort. Cox survival and negative binomial regression were used to compare the matched groups for all-cause mortality, hospitalizations, and blood transfusions.
Results: Of 1837 patients who met inclusion criteria, 1410 (77%) were successfully matched. The groups did not differ significantly in 31 characteristics reflecting sociodemographics, comorbidity, healthcare utilization, and renal function. There was no significant difference in mortality with early initiation. Those initiated early had a 17% lower risk of initial hospitalization and a 29% lower risk of transfusion compared with delayed initiation patients. Results did not differ between those with and without pre-ESA transfusion or hospitalization.
Conclusions: In nondialysis CKD, ESA initiation at Hb 10.0 to 11.0 g/dl compared with 8.0 to 9.9 g/dl is associated with reduced risk of blood transfusion and initial hospitalization.
Figures
Similar articles
-
Transfusion burden among patients with chronic kidney disease and anemia.Clin J Am Soc Nephrol. 2010 Apr;5(4):667-72. doi: 10.2215/CJN.06020809. Epub 2010 Mar 18. Clin J Am Soc Nephrol. 2010. PMID: 20299366 Free PMC article.
-
Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.Nephrol Dial Transplant. 2017 Nov 1;32(11):1892-1901. doi: 10.1093/ndt/gfw328. Nephrol Dial Transplant. 2017. PMID: 27672090
-
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.Kidney Int. 2011 Aug;80(3):288-94. doi: 10.1038/ki.2011.49. Epub 2011 Mar 9. Kidney Int. 2011. PMID: 21389972 Free PMC article.
-
[Regarding the optimal hemoglobin target range in renal anemia].Med Klin (Munich). 2008 Sep 15;103(9):633-7. doi: 10.1007/s00063-008-1102-3. Epub 2008 Sep 24. Med Klin (Munich). 2008. PMID: 18813886 Review. German.
-
The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.Am J Kidney Dis. 2019 Nov;74(5):667-674. doi: 10.1053/j.ajkd.2019.04.022. Epub 2019 Aug 5. Am J Kidney Dis. 2019. PMID: 31395400 Review.
Cited by
-
Treatment of anemia in difficult-to-manage patients with chronic kidney disease.Kidney Int Suppl (2011). 2021 Apr;11(1):26-34. doi: 10.1016/j.kisu.2020.12.006. Epub 2021 Mar 18. Kidney Int Suppl (2011). 2021. PMID: 33777493 Free PMC article.
-
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial.
-
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.Am J Nephrol. 2021;52(9):702-713. doi: 10.1159/000519043. Epub 2021 Oct 8. Am J Nephrol. 2021. PMID: 34628408 Free PMC article. Clinical Trial.
-
The role of the c-statistic in variable selection for propensity score models.Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):317-20. doi: 10.1002/pds.2074. Epub 2010 Dec 9. Pharmacoepidemiol Drug Saf. 2011. PMID: 21351315 Free PMC article.
-
Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study.Clin Exp Nephrol. 2012 Dec;16(6):930-7. doi: 10.1007/s10157-012-0640-4. Epub 2012 May 12. Clin Exp Nephrol. 2012. PMID: 22581064 Clinical Trial.
References
-
- Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955– 962, 2001 - PubMed
-
- Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ: Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 151: 492– 500, 2006 - PubMed
-
- Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S: Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44: 1017– 1023, 2004 - PubMed
-
- Goicoechea M, de Vinuesa SG, Gomez-Campdera F, Luno J: Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 93: S35– S38, 2005 - PubMed
-
- Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM: Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 14: 2919– 2925, 2003 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous